ライフサイエンスコーパス: ezetimibe

1 terol (7% [4-11] vs placebo and 8% [4-13] vs ezetimibe).

2 alirocumab, 1174 taking placebo, 618 taking ezetimibe).

3 -10.8]; p<0.0001 for all doses vs placebo or ezetimibe).

4 tatin monotherapy and 1.7% used statins plus ezetimibe.

5 62-70) versus placebo and 40% (36-45) versus ezetimibe.

6 51-69) versus placebo and 39% (32-47) versus ezetimibe.

7 g drug, the cholesterol absorption inhibitor ezetimibe.

8 rol at 12 weeks for evolocumab, placebo, and ezetimibe.

9 olesterol, particularly after treatment with ezetimibe.

10 its response to a cholesterol-lowering drug, ezetimibe.

11 ecurrent CV events and clinical benefit with ezetimibe.

12 h-fat/high-cholesterol diet, with or without ezetimibe.

13 st 8 weeks of statin therapy with or without ezetimibe.

14 xamined statins, and 2 examined statins plus ezetimibe.

15 ated with high-dose statins, with or without ezetimibe.

16 erated oral therapies, including statins and ezetimibe.

17 stable diet and statin dose, with or without ezetimibe.

18 of different doses of AMG145 and AMG145 plus ezetimibe.

19 mibe, and 1 patient (3.1%) receiving placebo/ezetimibe.

20 f SER access and the glucuronidation rate of ezetimibe.

21 sporter (Niemann-Pick C1-like 1) is the CAI, ezetimibe.

22 74 annually to be cost-effective relative to ezetimibe.

23 for consideration in patients intolerant to ezetimibe.

24 without the cholesterol absorption inhibitor ezetimibe.

25 Ezetimibe (1), a strong beta-lactamic cholesterol absorp

26 reatment with combined simvastatin 40 mg and ezetimibe 10 mg daily or placebo.

27 LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of ma

28 randomly assigned to simvastatin 20 mg plus ezetimibe 10 mg daily versus matching placebo.

29 biopsy-proven NASH were randomized to either ezetimibe 10 mg orally daily or placebo for 24 weeks.

30 neous placebo Q2W or QM both with daily oral ezetimibe 10 mg.

31 or 420 mg or placebo every 4 weeks; or oral ezetimibe 10 mg/day.

32 utaneous evolocumab (420 mg monthly) or oral ezetimibe (10 mg daily).

33 ) with placebo (every 2 weeks or monthly) or ezetimibe (10 mg or placebo daily; atorvastatin patients

34 The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared w

35 andomly assigned to simvastatin (20 mg) plus ezetimibe (10 mg) daily or matching placebo.

36 lacebo every 4 weeks 4.5% [-0.7 to 9.8]; and ezetimibe -14.7% [-18.6 to -10.8]; p<0.0001 for all dose

37 etimibe+phytosterol placebo, and (3) 10 mg/d ezetimibe+2.5 g phytosterols for 3 weeks each.

38 5% cholic acid, and 15% fat) without or with ezetimibe (7 mg/kg/d) for 6 wk.

39 ver 7 years were $453 per patient lower with ezetimibe (95% confidence interval, -$38 to -$869; P=0.0

40 vascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal chol

41 niacin ([ERN], 1,500 to 2,000 mg/day), with ezetimibe added as needed, in both groups, to maintain a

42 ; HR, 0.52; 95% CI, 0.31-0.86; P=0.011) with ezetimibe added to simvastatin therapy.

43 biomarkers in assessing likely benefit with ezetimibe added to statin therapy in post-ACS patients.

44 Alirocumab or ezetimibe added to statin therapy.

45 rging evidence of cardiovascular benefit for ezetimibe, alirocumab, and evolocumab positions these dr

46 ontrol (2161 mg/d; 95% CI, 1112 to 3209) and ezetimibe alone (1054 mg/d; 95% CI, 546 to 1561; both P<

47 o control (505 mg/d; 95% CI, 386 to 625) and ezetimibe alone (794 mg/d; 95% CI, 615 to 973).

48 mibe and phytosterols is more effective than ezetimibe alone in altering cholesterol metabolism.

49 sterol values during treatment with control, ezetimibe alone, and ezetimibe+phytosterols averaged 129

50 tatin combined with bile acid sequestrant or ezetimibe among high-risk patients intolerant of or unre

51 The addition of ezetimibe, an intestinal cholesterol absorption inhibito

52 atine kinase (N = 218, with 73 randomized to ezetimibe and 145 to evolocumab; entry mean LDL-C level,

53 as evidence for reduced ASCVD morbidity with ezetimibe and 2 PSCK9 inhibitors.

54 ts were assigned to receive simvastatin plus ezetimibe and 4620 to placebo.

55 mean age was 10.9 years; 8 patients were on ezetimibe and 7 on apheresis.

56 ommonly prescribed antihyperlipidemic drugs, ezetimibe and atorvastatin.

57 Declining ezetimibe and niacin use but not fibrate therapy among M

58 ASCVD risk, we found evidence of benefit for ezetimibe and PCSK9 inhibitors but not for niacin or cho

59 arly on decision making regarding the use of ezetimibe and PCSK9 inhibitors in patients with clinical

60 egnancy; use of pharmacotherapies, including ezetimibe and PCSK9 inhibitors; use of lipoprotein apher

61 Both ezetimibe and phytosterols inhibit cholesterol absorptio

62 ested the hypothesis that the combination of ezetimibe and phytosterols is more effective than ezetim

63 red by MRI-PDFF (mean difference between the ezetimibe and placebo arms -1.3%, P = 0.4).

64 tography-derived liver stiffness between the ezetimibe and placebo arms.

65 Altogether, the results demonstrate that ezetimibe and pranlukast can increase the yield of recom

66 t here two GALNS pharmacological chaperones, ezetimibe and pranlukast, identified by molecular dockin

67 y markers p62 and LC3B-II were alleviated by ezetimibe and pranlukast.

68 er agents available for prescription include ezetimibe and proprotein convertase subtilisin/kexin typ

69 tment, and consensus pathways suggest use of ezetimibe and proprotein convertase subtilisin/kexin typ

70 ficacy of the use of statins with or without ezetimibe and reductions in low-density lipoprotein chol

71 weekly; oral placebo and SC placebo monthly; ezetimibe and SC placebo biweekly; ezetimibe and SC plac

72 monthly; ezetimibe and SC placebo biweekly; ezetimibe and SC placebo monthly; oral placebo and evolo

73 7,717 post-ACS patients randomized either to ezetimibe and simvastatin or to placebo and simvastatin

74 ormin, thiazolidinediones, fibrates, niacin, ezetimibe and statins in improving the steatosis compone

75 encoding the respective molecular targets of ezetimibe and statins, have previously been used as prox

76 For ezetimibe and the PSCK9 inhibitors, rates of musculoskel

77 Through microsomal assays with ezetimibe and the transport inhibitor bromsulphthalein w

78 nt LDL-C reductions compared with placebo or ezetimibe and was well tolerated in patients with hyperc

79 ontinued all lipid-lowering treatment except ezetimibe and/or apheresis.

80 on with rosuvastatin 20 mg alone or added to ezetimibe and/or apheresis.

81 ) (31% [25-37] vs placebo and 26% [16-35] vs ezetimibe), and an increase in HDL cholesterol (7% [4-11

82 r 150 mg every 2 weeks) and control (placebo/ezetimibe), and analyzed by background statin type/dose.

83 alirocumab), NPC1L1 (encoding the target for ezetimibe), and APOB (encoding the target of mipomersen)

84 l (38% [32-44] vs placebo and 24% [16-31] vs ezetimibe), and lipoprotein(a) (31% [25-37] vs placebo a

85 % allocated to alirocumab, 6.5% allocated to ezetimibe, and 0% allocated to placebo).

86 , 6 patients (20.0%) receiving 420-mg AMG145/ezetimibe, and 1 patient (3.1%) receiving placebo/ezetim

87 statin monotherapy, 18.7% with statins plus ezetimibe, and 14% with add-on PCSK9 inhibitor.

88 Conventional therapy is with statins, ezetimibe, and apheresis.

89 ce interval: -13.8% to -0.8%; p = 0.02) with ezetimibe, and intermediate-risk patients (1 to 2 biomar

90 es, such as pretreatment with beta-blockers, ezetimibe, and proprotein convertase subtilisin kexin ty

91 eported in 36%, 40%, and 39% of evolocumab-, ezetimibe-, and placebo-treated patients, respectively.

92 ment MRI-PDFF was significantly lower in the ezetimibe arm (15%-11.6%, P < 0.016) but not in the plac

93 statin and dosage of their choice and added ezetimibe as needed.

94 Ezetimibe assignment was open label.

95 revent 4.3 million MACE compared with adding ezetimibe at $414,000 per QALY (80% UI, $277,000-$1,539,

96 r atorvastatin at a dose of 80 mg daily plus ezetimibe at a dose of 10 mg daily, for a run-in period

97 isation was stratified by concomitant use of ezetimibe at baseline.

98 completely offset the cost of the drug once ezetimibe becomes generic, and may lead to cost savings

99 tic microsomes, which influenced the rate of ezetimibe beta-D-glucuronide formation as determined in

100 t, bile acid sequestrants, ileal bypass, and ezetimibe) (between-group difference, P = .72).

101 is regulated by cholesterol binding and that ezetimibe blocks NPC1L1-GFP function by inhibiting its e

102 f various domains is needed for transfer and ezetimibe blocks transport by binding to multiple domain

103 ely prescribed cholesterol uptake inhibitor, ezetimibe, blocks NPC1L1; we show that residues that lie

104 d based upon the structure and properties of ezetimibe, but none remain in development.

105 onventional statin treatment with or without ezetimibe, but that it has the potential to induce liver

106 arotid atherosclerosis is indeterminate, but ezetimibe can be reasonably added to statin therapy as a

107 low-fat/no-cholesterol diet, with or without ezetimibe (cholesterol-lowering drug), and high-fat/high

108 Type of LDL-receptor mutation, use of ezetimibe, coexistent diabetes, and ASCVD status can bea

109 ar for high-dose simvastatin and simvastatin/ezetimibe combination therapy, but the magnitude of the

110 omatic AS patients randomized to simvastatin/ezetimibe combination versus placebo in the SEAS (Simvas

111 mptomatic patients randomized to simvastatin/ezetimibe combination versus placebo in the Simvastatin

112 Clinical outcome data with ezetimibe combined with simvastatin have recently become

113 wer cardiovascular hospitalization rate with ezetimibe compared with placebo (risk ratio, 0.95; 95% c

114 cremental LDL-C lowering attributable to the ezetimibe component reduces cardiovascular events beyond

115 week, randomized, double-blind, placebo- and ezetimibe-controlled study conducted between January and

116 week, randomized, double-blind, placebo- and ezetimibe-controlled, dose-ranging study conducted betwe

117 armacology of the cholesterol-lowering agent ezetimibe corroborates its potential carcinogenicity.

118 ompared with a statin alone, the addition of ezetimibe cost $81 000 (95% uncertainty interval [UI], $

119 Mid-intensity statin plus ezetimibe decreased LDL cholesterol level 5% to 15% and

120 Ezetimibe did not significantly reduce liver fat in NASH

121 monitor NPC1L1-GFP endocytosis and show that ezetimibe does not alter the rate of NPC1L1-GFP endocyto

122 ere was a significant increase in the use of ezetimibe, drug combinations with statins, and maximal L

123 stine tissues from 24-week-old offspring fed ezetimibe during lactation, compared with controls.

124 iemann-Pick C1-Like 1 (NPC1L1) receptor with ezetimibe, either alone or in combination with a 3-hydro

125 us the non-statin cholesterol-lowering drug, Ezetimibe (EZT) on severity of diabetic nephropathy.

126 -15%; 95% CI, -23% to -7.0%) for the placebo/ezetimibe group (P < .001).

127 (-63%; 95% CI, -71% to -55%) for the 420-mg/ezetimibe group compared with -14 mg/dL (-15%; 95% CI, -

128 oint at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastat

129 iter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter

130 o groups, and 26 (58%) of 45 patients in the ezetimibe group; no deaths or serious treatment-related

131 fewer patients allocated to simvastatin plus ezetimibe had a non-fatal myocardial infarction or died

132 Similarly, allocation to simvastatin plus ezetimibe had no significant effect on the prespecified

133 Ezetimibe improved cardiovascular outcomes when added to

134 Ezetimibe improves cardiovascular (CV) outcomes in patie

135 ients most likely to benefit from the use of ezetimibe in addition to statin therapy after acute coro

136 Treatment with ezetimibe in an amount sufficient to block intestinal ch

137 ic stenosis participating in the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study.

138 itial asymptomatic AS in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.

139 nation versus placebo in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.

140 years of follow-up in the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) study.

141 versus placebo in the SEAS (Simvastatin and Ezetimibe in Aortic Stenosis) study.

142 e used data from the SEAS trial (Simvastatin Ezetimibe in Aortic Stenosis) to assess what blood press

143 Lowering cholesterol plasma levels with ezetimibe in apoE(-/-) mice reversed iNKT function and M

144 te cost-effectiveness of PCSK9 inhibitors or ezetimibe in heterozygous FH or ASCVD.

145 f subcutaneous evolocumab compared with oral ezetimibe in hypercholesterolemic patients who are unabl

146 and monthly evolocumab with placebo and oral ezetimibe in patients with hypercholesterolemia in a pha

147 here is a gradient in the restrictiveness of ezetimibe in public-funded formularies (most to least st

148 afety of the combination of simvastatin plus ezetimibe in such patients.

149 mice with NaHS, but not N-acetylcysteine or ezetimibe, inhibited the accelerated atherosclerosis dev

150 Moreover, ezetimibe inhibits infection by all major HCV genotypes

151 Ezetimibe inhibits intestinal cholesterol absorption and

152 Ezetimibe interacts with the intestinal cholesterol abso

153 C1L1 does not require endocytosis; moreover, ezetimibe interferes with NPC1L1's cholesterol adsorptio

154 In humans, ezetimibe is extensively metabolized by hepatic and inte

155 therapy with statins is well established and ezetimibe is often used as an additional LDL-C-lowering

156 of the healthcare system, if treatment with ezetimibe is targeted to high-risk patients.

157 who may derive greater clinical benefit with ezetimibe is unknown.

158 how that co-administration of lovastatin and ezetimibe (L/E) significantly reverses hepatic triglycer

159 Ezetimibe lowers plasma levels of low-density lipoprotei

160 t compared alirocumab with controls (placebo/ezetimibe), mainly as add-on therapy to maximally tolera

161 te intensive statin therapy, with or without ezetimibe, many patients are unable to achieve recommend

162 The antiatherogenic effect of ezetimibe monitored by (99m)Tc-cAbVCAM1-5 SPECT showed a

163 One trial of ezetimibe monotherapy (n = 138) showed mean LDL-C decrea

164 ezetimibe therapy, switching from statins to ezetimibe monotherapy, having International Classificati

165 tatin (n=20) or 10 mg simvastatin plus 10 mg ezetimibe (n=19) for 6 weeks.

166 y 2 weeks (n=45) or every 4 weeks (n=45); or ezetimibe (n=45).

167 ulation of 1110 patients (fibrates, n = 220; ezetimibe, n = 890), 9.1% of fibrate users and 0.3% of e

168 ntensive review, including trials evaluating ezetimibe, niacin, cholesterol-ester transfer protein in

169 orresponding to treatment differences versus ezetimibe of 37% to 39% (p <0.001).

170 However, the impact of ezetimibe on cardiovascular-related hospitalizations and

171 The effect of ezetimibe on carotid atherosclerosis is indeterminate, b

172 analysis showing superiority of niacin over ezetimibe on change in carotid intima-media thickness (C

173 timibe significantly enhanced the effects of ezetimibe on whole-body cholesterol metabolism and plasm

174 sed within 90 days of a new prescription for ezetimibe or a fibrate.

175 cacy was similar regardless of age or use of ezetimibe or apheresis, and was maintained for 12 weeks.

176 The treatment of ezetimibe or atorvastatin alone decreased effectively th

177 2-week washout, patients were randomized to ezetimibe or evolocumab for 24 weeks.

178 pathways and algorithms regarding the use of ezetimibe or PCSK9 inhibitors in primary prevention pati

179 Statin therapy compared with addition of ezetimibe or PCSK9 inhibitors.

180 Adding ezetimibe or PCSK9 monoclonal antibodies to maximally to

181 Combined treatment of recombinant GALNS with ezetimibe or pranlukast produced an additive effect.

182 candidates for adding nonstatin medications (ezetimibe or proprotein convertase subtilisin/kexin type

183 mean LDL cholesterol to 1.4-1.8 mmol/L with ezetimibe or statins reduces cardiovascular events in pa

184 etic support for the repurposing of statins, ezetimibe, or mipomersen for AD prevention.

185 g, or 420 mg; AMG145 at 420 mg plus 10 mg of ezetimibe; or 10 mg of ezetimibe plus placebo.

186 vents (MACE) has been observed in statin and ezetimibe outcomes trials down to achieved levels of 54

187 The effect of formulary policy on the use of ezetimibe over time is unknown.

188 % more than placebo and 38% to 40% more than ezetimibe (p < 0.001 for all comparisons).

189 )H-tracer was 61% lower in mice treated with ezetimibe (P < 0.001).

190 ppear to derive benefit from the addition of ezetimibe (p interaction = 0.010).

191 nation of 80 mg of atorvastatin and 10 mg of ezetimibe (P<0.001 for all comparisons).

192 ibe placebo+phytosterol placebo, (2) 10 mg/d ezetimibe+phytosterol placebo, and (3) 10 mg/d ezetimibe

193 treatment with control, ezetimibe alone, and ezetimibe+phytosterols averaged 129 mg/dL (95% CI, 116 t

194 eived a phytosterol-controlled diet plus (1) ezetimibe placebo+phytosterol placebo, (2) 10 mg/d ezeti

195 420 mg plus 10 mg of ezetimibe; or 10 mg of ezetimibe plus placebo.

196 Lipid-lowering therapy with ezetimibe plus simvastatin improved clinical outcomes.

197 atins in individuals with CKD was shown with ezetimibe plus simvastatin versus placebo.

198 R in 18,015 individuals from the IMPROVE-IT (ezetimibe plus simvastatin versus simvastatin alone in i

199 lly available FDA-approved NPC1L1 antagonist ezetimibe potently blocks HCV uptake in vitro via a viri

200 on of intestinal cholesterol absorption with ezetimibe promotes antiatherosclerotic effects through i

201 ryl oleate-labeled human LDL to test whether ezetimibe promotes LDL-derived cholesterol fecal excreti

202 n of Niemann-Pick C1 Like 1 transporter with ezetimibe reduced the hypercholesterolemic effect of [Th

203 zebrafish with a cholesterol-lowering agent, ezetimibe, reduced susceptibility to S Typhi.

204 Inhibition of NPC1L1 by its inhibitor ezetimibe reduces stool output in specific pathogen-free

205 Compared with the combination of statin and ezetimibe, replacing ezetimibe with alirocumab cost $997

206 40 alirocumab, n = 1,894 control [placebo or ezetimibe]; representing 4,029 [alirocumab] and 2,114 [c

207 effects, the use of evolocumab compared with ezetimibe resulted in a significantly greater reduction

208 of follow-up, allocation to simvastatin plus ezetimibe resulted in an average LDL cholesterol differe

209 When added to statin therapy, ezetimibe resulted in incremental lowering of LDL choles

210 PC1L1-GFP) endocytosis failed to inhibit the ezetimibe-sensitive uptake of [(3)H]cholesterol from tau

211 trated lipid-altering efficacy and safety of ezetimibe, several CAIs have been identified; all to dat

212 Mice treated with ezetimibe showed a 173% higher LDL-cholesteryl ester pla

213 The addition of phytosterols to ezetimibe significantly enhanced the effects of ezetimib

214 or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels i

215 was higher in the placebo+simvastatin versus ezetimibe+simvastatin arm (KM rate 52.0% versus 49.8%, P

216 , which evaluated placebo+simvastatin versus ezetimibe+simvastatin in patients hospitalized with the

217 L) at 1 month were more likely randomized to ezetimibe/simvastatin (85%), had lower baseline LDL-C va

218 rol 50 to 125 mg/dL were randomized to 40 mg ezetimibe/simvastatin (E/S) or 40 mg placebo/simvastatin

219 in cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone wa

220 density lipoprotein cholesterol therapy with ezetimibe/simvastatin in IMPROVE-IT (IMProved Reduction

221 More patients treated with ezetimibe/simvastatin met dual targets than those treate

222 Significantly more patients treated with ezetimibe/simvastatin met prespecified and exploratory d

223 e analyzed in patients randomized to receive ezetimibe/simvastatin or placebo/simvastatin in IMPROVE-

224 cluding the first and all recurrent strokes, ezetimibe/simvastatin reduced stroke of any etiology (HR

225 were randomized to a placebo/simvastatin or ezetimibe/simvastatin regimen and followed for a median

226 the first event, would also be reduced with ezetimibe/simvastatin therapy.

227 s within a randomized, double-blind trial of ezetimibe/simvastatin versus placebo/simvastatin (IMPROV

228 ence interval [CI], 0.73-1.00; P=0.052) with ezetimibe/simvastatin versus placebo/simvastatin, driven

229 The use of ezetimibe/simvastatin versus simvastatin in IMPROVE-IT (

230 events were significantly reduced by 9% with ezetimibe/simvastatin vs placebo/simvastatin (incidence-

231 CRP targets and outcomes for simvastatin and ezetimibe/simvastatin was prespecified in Improved Reduc

232 eduction in CV death/MI/iCVA at 7 years with ezetimibe/simvastatin, thus translating to a number-need

233 er acute coronary syndrome to simvastatin or ezetimibe/simvastatin.

234 polymorphisms in the NPC1L1 gene (target of ezetimibe), the HMGCR gene (target of statins), or both

235 y applied for stereoselective preparation of Ezetimibe, the commercial cholesterol absorption inhibit

236 ponded modestly to maximum rosuvastatin plus ezetimibe therapy, even in combination with a PCSK9 mono

237 l prespecified subgroups had lower cost with ezetimibe therapy, patients with diabetes mellitus, pati

238 py, including moderate-intensity statin plus ezetimibe therapy, rates of nonadherence are reported in

239 ned as down-titrating statins and initiating ezetimibe therapy, switching from statins to ezetimibe m

240 : uptitration to atorvastatin, 80 mg; add-on ezetimibe therapy; add-on alirocumab therapy, 75 mg (a P

241 sms may contribute to the benefits of adding ezetimibe to a statin therapy.

242 ing the efficacy of evolocumab, placebo, and ezetimibe to improve lipid parameters in adult patients

243 Adding ezetimibe to reduce low-density LDL-C by 20% would provi

244 demonstrated no benefit with the addition of ezetimibe to simvastatin (Pint =0.034).

245 investigated the efficacy of the addition of ezetimibe to simvastatin for the prevention of stroke an

246 The addition of ezetimibe to simvastatin in patients stabilized after ac

247 Adding ezetimibe to statin therapy did not increase discontinua

248 derive greatest benefit from the addition of ezetimibe to statin therapy for secondary prevention aft

249 rdial infarction/stroke with the addition of ezetimibe to statin therapy in patients at higher risk o

250 Addition of ezetimibe to statin therapy in patients with a recent ac

251 on of clinical benefits from the addition of ezetimibe to statin therapy in subjects with acute coron

252 Addition of ezetimibe to statin therapy reduces the risk of recurren

253 d not appear to benefit from the addition of ezetimibe to statin therapy.

254 y high absolute benefit from the addition of ezetimibe to statin therapy.

255 t potential for benefit from the addition of ezetimibe to statin therapy.

256 In IMPROVE-IT, the benefit of adding ezetimibe to statin was enhanced in patients with DM and

257 503,000 per QALY gained compared with adding ezetimibe to statins (80% uncertainty interval [UI], $49

258 ity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C and hs-CRP.

259 l (55% [47-63] vs placebo and 34% [26-41] vs ezetimibe), total cholesterol (38% [32-44] vs placebo an

260 g was stopped for muscle symptoms in 5 of 73 ezetimibe-treated patients (6.8%) and 1 of 145 evolocuma

261 Muscle symptoms were reported in 28.8% of ezetimibe-treated patients and 20.7% of evolocumab-treat

262 2% of evolocumab-treated patients and 23% of ezetimibe-treated patients.

263 the recommendation for statin or statin with ezetimibe treatment of adults aged 50 years or older wit

264 ) were from statin trials, 6209 (28.9%) from ezetimibe trials, and 3533 (16.4%) from PCSK9 inhibitor

265 er or lower than 4.1 mmol/L) and by baseline ezetimibe use (yes/no).

266 Ezetimibe use has steadily increased in Canada during th

267 a from June 2003 to December 2012 to examine ezetimibe use in these 4 provinces to better understand

268 Ezetimibe use peaked at 12.1% and declined to 4.6% by th

269 Ezetimibe use remains common, increasing during the past

270 The gradient in ezetimibe use was related to variability in restrictiven

271 betes mellitus, a defective allele mutation, ezetimibe use, and the absence of previous ASCVD were pr

272 found regional variations in the patterns of ezetimibe use.

273 iacin, fibrates, bile acid sequestrants, and ezetimibe) use among Medicare beneficiaries with coronar

274 Compared with ezetimibe users (n = 61,831), fibrate users (n = 19,072)

275 n = 890), 9.1% of fibrate users and 0.3% of ezetimibe users had an increase in serum creatinine leve

276 RD (1057 [33.9%] cases with simvastatin plus ezetimibe versus 1084 [34.6%] cases with placebo; rate r

277 erefore, we aimed to examine the efficacy of ezetimibe versus placebo in reducing liver fat by the ma

278 tinal bleeding, and a study of simvastatin + ezetimibe versus simvastatin alone in 6-month cardiovasc

279 Trial) to examine the impact of simvastatin-ezetimibe versus simvastatin-placebo on cardiovascular-r

280 lerotic events (526 [11.3%] simvastatin plus ezetimibe vs 619 [13.4%] placebo; rate ratio [RR] 0.83,

281 LDL-C level at week 24 with ezetimibe was 181.5 mg/dL; mean percent change, -16.7% (

282 he mean of weeks 22 and 24, LDL-C level with ezetimibe was 183.0 mg/dL; mean percent LDL-C change, -1

283 Ezetimibe was not significantly better than placebo at r

284 n (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and pla

285 ultiple drugs interact with OATP1B3-1B7; for ezetimibe, we were able to show that SER access and meta

286 g/dL) despite statin therapy with or without ezetimibe were randomized 1:1:1 to AMG 145 350 mg, AMG 1

287 Subjects taking simvastatin and/or ezetimibe were randomized to receive extended-release (E

288 rwise meta-analysis, statins with or without ezetimibe were shown to be efficacious in reducing major

289 on a stable dose of statin (with or without ezetimibe), were randomly assigned equally, through an i

290 Ezetimibe, when added to simvastatin therapy, reduces ca

291 Ezetimibe, when added to simvastatin, reduces cardiovasc

292 Ezetimibe, which interacted with OATP1B3-1B7, is highly

293 (for 3 weeks between birth and weaning) with ezetimibe, which is secreted into milk.

294 tine and liver and is the target of the drug ezetimibe, which is used to treat hypercholesterolemia.

295 One such inhibitor was ezetimibe, which not only inhibited OATP1B3-1B7 but is a

296 Examples include ezetimibe, which targets Niemann-Pick C1-like protein, a

297 mbination of statin and ezetimibe, replacing ezetimibe with alirocumab cost $997 000 (UI, $254 000 to

298 In 1 trial (n = 248), ezetimibe with simvastatin resulted in greater LDL-C red

299 espite intensive statin use, with or without ezetimibe, with minimal adverse events and good tolerabi

300 Allocation to simvastatin plus ezetimibe yielded an average LDL cholesterol difference